|
|
 Previous Article | Table of Contents | Next Article 
Recombinant human granulocyte/macrophage colony-stimulating factor enhances
monocyte cytotoxicity and secretion of tumor necrosis factor alpha and
interferon in cancer patients
EJ Wing, DM Magee, TL Whiteside, SS Kaplan and RK Shadduck
Montefiore Hospital, Department of Medicine, University of Pittsburgh
School of Medicine, PA 15213.
The colony-stimulating factors (CSFs) promote the proliferation and
differentiation of hematopoietic precursors and more recently have been
shown to amplify the functions of mature phagocytes in vitro. In this study
recombinant human granulocyte/macrophage colony-stimulating factor
(rGM-CSF) was administered to cancer patients to determine whether the
cytotoxic and secretory activity of their blood monocytes could be
enhanced. Patients with refractory neoplastic disease were treated with
rGM-CSF either as a single bolus or as a constant infusion for 14 days at
either 100 or 500 micrograms/m2 per day. As has been reported by others,
the number of peripheral blood monocytes and granulocytes rose markedly in
a dose-response fashion during infusion with rGM-CSF. The functional
capacity of monocytes was increased by rGM- CSF, since the cytotoxicity of
monocytes against antibody-coated xenogeneic cells was increased during the
constant infusion compared to baseline. In addition, monocytes harvested
during the constant infusion and stimulated with lipopolysaccharide (LPS)
in vitro secreted increased quantities of tumor necrosis factor alpha
(TNF-alpha) and interferon (IFN). These data indicate that rGM-CSF can
enhance both the number and the function of peripheral blood monocytes in
vivo.
Volume 73,
Issue 3,
pp. 643-646,
02/15/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Cartron, H. Watier, J. Golay, and P. Solal-Celigny
From the bench to the bedside: ways to improve rituximab efficacy
Blood,
November 1, 2004;
104(9):
2635 - 2642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Haynes, J. A. Trapani, M. W. L. Teng, J. T. Jackson, L. Cerruti, S. M. Jane, M. H. Kershaw, M. J. Smyth, and P. K. Darcy
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors
Blood,
October 16, 2002;
100(9):
3155 - 3163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Lawson and J. M. Kirkwood
Granulocyte-Macrophage Colony-Stimulating Factor: Another Cytokine With Adjuvant Therapeutic Benefit in Melanoma?
J. Clin. Oncol.,
April 1, 2000;
18(8):
1603 - 1605.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Spitler, M. L. Grossbard, M. S. Ernstoff, G. Silver, M. Jacobs, F. A. Hayes, and S. J. Soong
Adjuvant Therapy of Stage III and IV Malignant Melanoma Using Granulocyte-Macrophage Colony-Stimulating Factor
J. Clin. Oncol.,
April 1, 2000;
18(8):
1614 - 1621.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. G. MacEwen, I. D. Kurzman, D. M. Vail, R. R. Dubielzig, K. Everlith, B. R. Madewell, C. O. Rodriguez Jr., B. Phillips, C. H. Zwahlen, J. Obradovich, et al.
Adjuvant Therapy for Melanoma in Dogs: Results of Randomized Clinical Trials Using Surgery, Liposome-encapsulated Muramyl Tripeptide, and Granulocyte Macrophage Colony-stimulating Factor
Clin. Cancer Res.,
December 1, 1999;
5(12):
4249 - 4258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O. Armitage
Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor
Blood,
December 15, 1998;
92(12):
4491 - 4508.
[Full Text]
[PDF]
|
|
|
|
|
